Business Context and Reporting Period
Company: Amgen Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2008
Business Overview: Amgen is a global biotechnology company discovering, developing, manufacturing, and marketing human therapeutics. Principal products include Aranesp, EPOGEN, Neulasta, NEUPOGEN, and ENBREL. The company operates in a single segment: human therapeutics.
Key Financial Metrics
| Metric (in millions) | Three Months Ended Sept 30, 2008 | Nine Months Ended Sept 30, 2008 |
|---|---|---|
| Total Revenues | $3,875 | $11,252 |
| Product Sales | $3,784 | $11,013 |
| Operating Income | $1,483 | $4,077 |
| Net Income | $1,158 | $3,235 |
| Diluted EPS | $1.09 | $3.00 |
| Cash from Operating Activities | N/A | $4,591 |
| Cash & Cash Equivalents | $2,522 | $2,522 |
| Marketable Securities | $7,235 | $7,235 |
| Total Debt Outstanding | $11,176 | $11,176 |
Note: Operating margins for the nine months ended Sept 30, 2008 were approximately 36.2% ($4,077 / $11,252). Net margins were approximately 28.7%.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 7% for the three months and 3% for the nine months ended September 30, 2008, compared to the prior year. International sales grew 20% (three months) and 16% (nine months), aided by favorable foreign currency exchange rates.
- Profitability Surge: Net income for the three months ended September 30, 2008, was $1,158 million, a significant increase from $201 million in the same period in 2007. This improvement is largely due to the absence of a $590 million write-off of acquired in-process research and development (IPR&D) recorded in the prior year.
- Expense Reduction: Operating expenses decreased significantly year-over-year. "Other charges" dropped from $254 million to $12 million (three months) and from $543 million to $306 million (nine months), reflecting the completion of major restructuring actions initiated in 2007.
- Product Performance:
- Aranesp: Sales decreased 13% for the nine months due to regulatory and reimbursement restrictions in the U.S. supportive cancer care setting.
- Neulasta/NEUPOGEN: Sales increased 10% for the nine months, driven by demand growth and conversion from NEUPOGEN to Neulasta.
- ENBREL: Sales increased 13% for the nine months, supported by higher demand and price increases.
Guidance, Outlook, Risks, and Unusual Items
- Restructuring Plan: Amgen announced an updated estimate for its restructuring plan. Total expected charges are now $850 million to $925 million (up from a prior estimate of $775 million to $825 million). Approximately $790 million has been incurred through September 30, 2008, with remaining costs expected to be incurred through 2009.
- Regulatory Risks (ESAs): Significant risks remain regarding Erythropoiesis-Stimulating Agents (ESAs) like Aranesp and EPOGEN. Recent FDA label changes (August 2008) and CMS reimbursement restrictions have materially impacted sales. A proposed Risk Evaluation and Mitigation Strategy (REMS) for Aranesp in oncology is pending.
- Legal Proceedings: The company recorded a $267 million loss accrual in the nine months ended September 30, 2008, primarily related to the settlement of the Ortho Biotech antitrust suit. Other significant litigation includes patent disputes with Roche (regarding EPO patents) and Ariad (regarding ENBREL).
- Accounting Changes: Amgen expects the adoption of FSP APB 14-1 in Q1 2009, which will require bifurcation of convertible debt components. This is expected to have a material adverse impact on reported net income due to increased non-cash interest expense, though it will not affect cash flows.
- Capital Markets: The company noted extreme volatility in credit markets. A $178 million commitment in its credit facility provided by a Lehman Brothers subsidiary is no longer accessible due to Lehman's bankruptcy.
Investor Verification Checklist
- Restructuring Costs: Verify the final total cost of the restructuring plan and the timing of remaining cash outflows through 2009.
- ESA Reimbursement Impact: Monitor the long-term impact of the August 2008 FDA label changes and CMS reimbursement policies on Aranesp and EPOGEN sales volumes and pricing.
- Legal Settlements: Confirm the final terms and cash impact of the Ortho Biotech antitrust settlement and the status of the Roche patent litigation.
- Accounting Impact: Assess the quantitative impact of the upcoming FSP APB 14-1 adoption on future reported earnings and interest expense.
- Debt Maturity: Review the company's liquidity position relative to the $1.0 billion floating rate notes maturing in November 2008 and the $1.0 billion notes due in 2009.